Skip to main content
Top
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | NSCLC | Research article

Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea

Authors: Ji Young Park, Ye Jin Lee, Taehee Kim, Chang Youl Lee, Hwan Il Kim, Joo-Hee Kim, Sunghoon Park, Yong Il Hwang, Ki-Suck Jung, Seung Hun Jang

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The COVID-19 pandemic is predicted to significantly affect patients with lung cancer, owing to its rapid progression and high mortality. Studies on lung cancer diagnosis and treatment during an epidemic are lacking. We analyzed the impact of COVID-19 on lung cancer diagnosis in Korea, where lung cancer incidence continues to rise.

Methods

The number of newly diagnosed lung cancer cases in three university-affiliated hospitals during the pandemic and their clinical features were compared with lung cancer cases diagnosed during the same period in the past 3 years. The effectiveness of measures taken by the study hospitals to prevent nosocomial transmission was reviewed.

Results

A total of 612 patients were diagnosed with lung cancer from February through June, 2017–2020. During the pandemic, the number of patients who sought consultation at the division of pulmonology of study hospitals dropped by 16% from the previous year. Responding to the pandemic, the involved hospitals created physically isolated triage areas for patients with acute respiratory infection symptoms. Wide-range screening and preventive measures were implemented, thus minimizing the delay in lung cancer diagnosis. No patient acquired COVID-19 due to hospital exposure. The proportion of patients with stage III–IV non-small-cell lung cancer (NSCLC) significantly increased (2020: 74.7% vs. 2017: 57.9%, 2018: 66.7%, 2019: 62.7%, p = 0.011). The number of lung cancers diagnosed during this period and the previous year remained the same.

Conclusions

The proportion of patients with advanced NSCLC increased during the COVID-19 pandemic.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Kansagra AP, Goyal MS, Hamilton S, Albers GW. Collateral effect of Covid-19 on stroke evaluation in the United States. N Engl J Med. 2020;383(4):400–1.CrossRefPubMed Kansagra AP, Goyal MS, Hamilton S, Albers GW. Collateral effect of Covid-19 on stroke evaluation in the United States. N Engl J Med. 2020;383(4):400–1.CrossRefPubMed
4.
go back to reference Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung S-H, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383:691.CrossRefPubMed Solomon MD, McNulty EJ, Rana JS, Leong TK, Lee C, Sung S-H, et al. The Covid-19 pandemic and the incidence of acute myocardial infarction. N Engl J Med. 2020;383:691.CrossRefPubMed
5.
go back to reference Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020;383(5):496–8.CrossRefPubMed Baldi E, Sechi GM, Mare C, Canevari F, Brancaglione A, Primi R, et al. Out-of-hospital cardiac arrest during the Covid-19 outbreak in Italy. N Engl J Med. 2020;383(5):496–8.CrossRefPubMed
6.
go back to reference Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020;25(6):e936–e45.CrossRefPubMedPubMedCentral Al-Shamsi HO, Alhazzani W, Alhuraiji A, Coomes EA, Chemaly RF, Almuhanna M, et al. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. Oncologist. 2020;25(6):e936–e45.CrossRefPubMedPubMedCentral
9.
go back to reference Park JY, Jang SH, Kim HI, Kim J-H, Park S, Hwang YI, et al. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. BMC Cancer. 2019;19(1):574.CrossRefPubMedPubMedCentral Park JY, Jang SH, Kim HI, Kim J-H, Park S, Hwang YI, et al. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. BMC Cancer. 2019;19(1):574.CrossRefPubMedPubMedCentral
10.
go back to reference Lee H, Lee H, Song K-H, Kim ES, Park JS, Jung J, et al. Impact of public health interventions on seasonal influenza activity during the SARS-CoV-2 outbreak in Korea. Clin Infect Dis. 2020:ciaa672. Lee H, Lee H, Song K-H, Kim ES, Park JS, Jung J, et al. Impact of public health interventions on seasonal influenza activity during the SARS-CoV-2 outbreak in Korea. Clin Infect Dis. 2020:ciaa672.
12.
go back to reference Wahidi MM, Shojaee S, Lamb CR, Ost D, Maldonado F, Eapen G, et al. The use of bronchoscopy during the COVID-19 pandemic: CHEST/AABIP guideline and expert panel report. Chest. 2020:S0012–3692(20)30850–3. Wahidi MM, Shojaee S, Lamb CR, Ost D, Maldonado F, Eapen G, et al. The use of bronchoscopy during the COVID-19 pandemic: CHEST/AABIP guideline and expert panel report. Chest. 2020:S0012–3692(20)30850–3.
13.
go back to reference Dignani MC, Costantini P, Salgueira C, Jordán R, Guerrini G, Valledor A, et al. Pandemic 2009 influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000Research. 2014;3:221.CrossRefPubMed Dignani MC, Costantini P, Salgueira C, Jordán R, Guerrini G, Valledor A, et al. Pandemic 2009 influenza A (H1N1) virus infection in cancer and hematopoietic stem cell transplant recipients; a multicenter observational study. F1000Research. 2014;3:221.CrossRefPubMed
14.
go back to reference Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158(1):406–15.CrossRefPubMed Mazzone PJ, Gould MK, Arenberg DA, Chen AC, Choi HK, Detterbeck FC, et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST expert panel report. Chest. 2020;158(1):406–15.CrossRefPubMed
15.
go back to reference Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.CrossRefPubMedPubMedCentral Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–7.CrossRefPubMedPubMedCentral
16.
go back to reference Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049–55.CrossRefPubMed Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049–55.CrossRefPubMed
17.
go back to reference Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–1.CrossRefPubMedPubMedCentral Dinmohamed AG, Visser O, Verhoeven RHA, Louwman MWJ, van Nederveen FH, Willems SM, et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020;21(6):750–1.CrossRefPubMedPubMedCentral
18.
go back to reference Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023.CrossRefPubMedPubMedCentral Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020;21:1023.CrossRefPubMedPubMedCentral
19.
go back to reference Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035.CrossRefPubMedPubMedCentral Sud A, Torr B, Jones ME, Broggio J, Scott S, Loveday C, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. Lancet Oncol. 2020;21:1035.CrossRefPubMedPubMedCentral
20.
go back to reference Chen Y-M, Perng R-P, Chu H, Tsai C-M, Whang-Peng J. Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms. Lung Cancer. 2004;45(1):39–43.CrossRefPubMed Chen Y-M, Perng R-P, Chu H, Tsai C-M, Whang-Peng J. Impact of severe acute respiratory syndrome on the status of lung cancer chemotherapy patients and a correlation of the signs and symptoms. Lung Cancer. 2004;45(1):39–43.CrossRefPubMed
21.
go back to reference Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–90.CrossRefPubMed Arons MM, Hatfield KM, Reddy SC, Kimball A, James A, Jacobs JR, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020;382(22):2081–90.CrossRefPubMed
22.
go back to reference Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J. 2004;24(6):898–904.CrossRefPubMed Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist referral time. Eur Respir J. 2004;24(6):898–904.CrossRefPubMed
23.
go back to reference Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020;31:1065.CrossRefPubMed Sud A, Jones ME, Broggio J, Loveday C, Torr B, Garrett A, et al. Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic. Ann Oncol. 2020;31:1065.CrossRefPubMed
24.
go back to reference Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med. 2020;8(6):542–4.CrossRefPubMedPubMedCentral Calabrò L, Peters S, Soria JC, Di Giacomo AM, Barlesi F, Covre A, et al. Challenges in lung cancer therapy during the COVID-19 pandemic. Lancet Respir Med. 2020;8(6):542–4.CrossRefPubMedPubMedCentral
25.
go back to reference Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18.CrossRefPubMedPubMedCentral Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907–18.CrossRefPubMedPubMedCentral
26.
go back to reference Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386–96.CrossRefPubMed Luo J, Rizvi H, Preeshagul IR, Egger JV, Hoyos D, Bandlamudi C, et al. COVID-19 in patients with lung cancer. Ann Oncol. 2020;31(10):1386–96.CrossRefPubMed
27.
go back to reference Infante M, Berghmans T, Heuvelmans MA, Hillerdal G, Oudkerk M. Slow-growing lung cancer as an emerging entity: from screening to clinical management. Eur Respir J. 2013;42(6):1706–22.CrossRefPubMed Infante M, Berghmans T, Heuvelmans MA, Hillerdal G, Oudkerk M. Slow-growing lung cancer as an emerging entity: from screening to clinical management. Eur Respir J. 2013;42(6):1706–22.CrossRefPubMed
28.
go back to reference Yuan P, Cao JL, Rustam A, Zhang C, Yuan XS, Bao FC, et al. Time-to-progression of NSCLC from early to advanced stages: an analysis of data from SEER registry and a single institute. Sci Rep. 2016;6(1):28477.CrossRefPubMedPubMedCentral Yuan P, Cao JL, Rustam A, Zhang C, Yuan XS, Bao FC, et al. Time-to-progression of NSCLC from early to advanced stages: an analysis of data from SEER registry and a single institute. Sci Rep. 2016;6(1):28477.CrossRefPubMedPubMedCentral
29.
go back to reference Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–9.CrossRefPubMed Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132(1):193–9.CrossRefPubMed
Metadata
Title
Collateral effects of the coronavirus disease 2019 pandemic on lung cancer diagnosis in Korea
Authors
Ji Young Park
Ye Jin Lee
Taehee Kim
Chang Youl Lee
Hwan Il Kim
Joo-Hee Kim
Sunghoon Park
Yong Il Hwang
Ki-Suck Jung
Seung Hun Jang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07544-3

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine